Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Empagliflozin/Linagliptin/Metformin XR FDC vs Free Combination
NCT03629054Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin + linagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve From 0 to Last Quantifiable Data Point, Area Under the Concentration-time Curve From 0 to 72 Hours and 1 more. Started Aug 2018; status: completed.
02
Drugs
empagliflozin + linagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03629054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629054.